[July 21, 2016]

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2016 - Research and Markets

Research and Markets has announced the addition of the "Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2016" report to their offering.

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) pipeline target constitutes close to 10 molecules, out of which approximately 9 molecules are developed by Companies and the remaining by Universities/Institutes.

Furthermore, the publisher says; Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)- also known as Colony Stimulating Factor 2 (CSF2)- is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts that functions as a cytokine. GM-CSF plays a role in embryonic development by functioning as an embryokine produced b reproductive tract.

The report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2016' outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Companies Mentioned

• Aduro BioTech, Inc.
• Amgen Inc.
• BriaCell Therapeutics Corp.
• GlaxoSmithKline Plc
• Humabs BioMed SA
• KaloBios Pharmaceuticals, Inc.
• Morphotek, Inc.
• Sillajen Biotherapeutics
• Takeda Pharmaceutical Company Limited

For more information visit http://www.researchandmarkets.com/research/rqnnkg/granulocyte

View source version on businesswire.com: http://www.businesswire.com/news/home/20160721005662/en/

[ Back To TMCnet.com's Homepage ]